Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
Conditions
Leukemia
Conditions: official terms
Leukemia - Leukemia, Myeloid - Leukemia, Myeloid, Acute
Conditions: Keywords
adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), untreated adult acute myeloid leukemia, adult acute basophilic leukemia, adult acute eosinophilic leukemia, adult erythroleukemia (M6a), adult pure erythroid leukemia (M6b), adult acute minimally differentiated myeloid leukemia (M0), adult acute monoblastic leukemia (M5a), adult acute monocytic leukemia (M5b), adult acute myeloblastic leukemia with maturation (M2), adult acute myeloblastic leukemia without maturation (M1), adult acute myelomonocytic leukemia (M4)
Study Type
Observational
Study Phase
N/A
Study Design
N/A
Intervention
Name: mutation analysis Type: Genetic
Name: protein analysis Type: Genetic
Name: laboratory biomarker analysis Type: Other
Name: liquid chromatography Type: Other
Name: mass spectrometry Type: Other
Overall Status
Not yet recruiting
Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and lean more about biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in blood samples from patients with acute myeloid leukemia.
Detailed Description
OBJECTIVES:

Primary

- To determine if serum 2-hydroxyglutarate (2HG) is only detected in acute myeloid leukemia (AML) patients with isocitrate dehydrogenase (IDH) mutations.

Secondary

- To determine if the level of serum 2HG impacts leukemia-free survival (LFS).

- To determine if the level of serum 2HG impacts overall survival (OS).

- To determine if serum 2HG is undetectable at the time of documented clinical remission (CR) in IDH-mutated patients.

OUTLINE: Archived serum samples are analyzed for 2-hydroxyglutarate expression by reverse-phase liquid chromatography coupled to mass spectrometry. Results are then compared with presence or absence of an IDH mutation, patients' clinical outcome, as well as age, sex, white blood cell count at diagnosis, platelet count, bone marrow blast percentage at diagnosis, circulating (serum) percentage at diagnosis, cytogenetic risk group, presence of FLT3, NPMN1, and/or TET2 mutations, specific IDH mutation, and randomization treatment group allocation.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 60 Years
Minimum Age: 17 Years
Gender: Both
Criteria: DISEASE CHARACTERISTICS:

- Morphologically confirmed acute myeloid leukemia (AML)

- Newly diagnosed with AML

- Serum samples from patients enrolled on the ECOG-1900 clinical trial between 2002 and 2008

- Patients with or without isocitrate dehydrogenase (IDH) mutations

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Received 2 different doses of standard induction chemotherapy on ECOG-1900
Location
Start Date
August 2011
Sponsors
Eastern Cooperative Oncology Group
Source
National Cancer Institute (NCI)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page